These first Phase I trials for SB1518 comprise of ascending dose studies conducted at several leading clinical sites in the US. The trials are expected to enroll up to 60 patients and are designed to determine the maximum tolerated dose and to assess the pharmacokinetics and overall safety profile of SB1518.
In addition to SB1518, S BIO has a robust pipeline including SB939, the company’s lead histone deacetylase inhibitor, which is currently in Phase I trials in Singapore and Canada.
Jan-Anders Karlsson, CEO of S BIO, said: “The entry of SB1518 into the clinical phase marks an important milestone for S BIO and potentially offers a new targeted therapy for this group of difficult-to-treat patients that represent a significant unmet medical need. SB1518 has demonstrated exciting anti-proliferative and anti-tumor activity, combined with excellent tolerability in relevant in vitro and in vivo models.”